Verrica Pharmaceuticals Inc. (VRCA): Price and Financial Metrics


Verrica Pharmaceuticals Inc. (VRCA)

Today's Latest Price: $9.92 USD

0.54 (5.76%)

Updated Dec 4 4:00pm

Add VRCA to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

VRCA Stock Price Chart Interactive Chart >

Price chart for VRCA

VRCA Price/Volume Stats

Current price $9.92 52-week high $17.60
Prev. close $9.38 52-week low $6.02
Day low $9.33 Volume 45,400
Day high $10.00 Avg. volume 111,365
50-day MA $8.50 Dividend yield N/A
200-day MA $9.67 Market Cap 256.59M

Verrica Pharmaceuticals Inc. (VRCA) Company Bio

Verrica Pharmaceuticals Inc. develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790. The company is based in West Chester, Pennsylvania.

Most Popular Stories View All

• Are Stocks Off to the Races in December?

• 4 Growth Stocks That Could Soar in December

• Is BlackBerry a BUY or SELL After Announcing a Partnership with Amazon?

• 3 Under-the-Radar Electric Vehicle Stocks with Explosive Potential

• Blink Charging: Buy, Sell, or Hold?

View All Top Stories

VRCA Latest News Stream

Event/Time News Detail
Loading, please wait...
View All VRCA News

VRCA Latest Social Stream

Loading social stream, please wait...

View Full VRCA Social Stream

Latest VRCA News From Around the Web

Below are the latest news stories about Verrica Pharmaceuticals Inc that investors may wish to consider to help them evaluate VRCA as an investment opportunity.

VRCA Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Verrica Pharmaceuticals Inc. and Lead Plaintiff Deadline: September 14, 2020

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ: VRCA) and certain of its officers, on behalf of…

PR Newswire | September 14, 2020

DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, CA - (NewMediaWire) - September 11, 2020 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (NASDAQ: VRCA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 16, 2019 and June 29, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before September 14, 2020. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA...

NewMediaWire | September 11, 2020

Verrica Pharma +7.1% after director, management buy shares

Verrica Pharmaceutcials (VRCA) closed after-hours trading up 7.1% after disclosing a number of insider sales from Thursday and Friday. Director Sean Stalfort bought a total of 31,250 shares across the two days (15,550 at an average price of $6.45, and 15,700 at an average price of $6.38) - a total...

Seeking Alpha | August 18, 2020

Insider Buys Verrica Pharmaceuticals Stock

Shares of Verrica Pharmaceuticals Inc (NASDAQ:VRCA) moved higher by 14.7% from the previous closing price. A Form 4 filing filed with the SEC on Tuesday, …

Benzinga | August 18, 2020

The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) ABIOMED, Inc. (NASDAQ: ABMD ) (FDA approved the emergency use of Abiomed's Impella heart pump in combination with an oxygen machine to treat Covid-19 patients who suffer heart and lung failure) Allovir Inc (NASDAQ: ALVR ) (IPOed Thursday) Alterity Therapeutics Ltd (NASDAQ: ATHE ) ( announced positive preclinical data for its lead drug in Multiple System Atrophy) ALX Oncology Holdings Inc (NASDAQ: ALXO ) Cardiff Oncology Inc (NASDAQ: CRDF ) Cocrystal Pharma Inc (NASDAQ: COCP ) (announced the publication of positive preclinical animal studies of coronavirus antiviral compounds in a medical journal) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Fulgent Genetics Inc (NASDAQ: FLGT ) Hologic, Inc. (NASDAQ: HOLX ) Inari Medical Inc (NA...

Benzinga | August 5, 2020

Read More 'VRCA' Stories Here

VRCA Price Returns

1-mo 30.53%
3-mo 18.10%
6-mo -20.89%
1-year -27.11%
3-year N/A
5-year N/A
YTD -37.57%
2019 94.97%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8281 seconds.